1997
DOI: 10.1016/s0360-3016(96)00614-1
|View full text |Cite
|
Sign up to set email alerts
|

Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

2
54
0
1

Year Published

1998
1998
2017
2017

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 86 publications
(57 citation statements)
references
References 24 publications
2
54
0
1
Order By: Relevance
“…In our Phase II feasibility trial, 20 patients (80%) received a total cisplatin dose of more than 240 mg/m 2 concurrent with RT and achieved an RDI of cisplatin of 0.83. Moreover, the incidence of adverse events was almost identical to that in previous pivotal trials (1,2,4) and no treatment-related deaths or severe complications with the reconstruction flap were seen. Considering that most patients (72%) were ECOG-PS 0 and the small sample size, these results indicted the tolerability and feasibility of adjuvant 3W-CDDP/RT for Japanese patients with post-operative high-risk SCCHN.…”
Section: Discussionsupporting
confidence: 77%
See 1 more Smart Citation
“…In our Phase II feasibility trial, 20 patients (80%) received a total cisplatin dose of more than 240 mg/m 2 concurrent with RT and achieved an RDI of cisplatin of 0.83. Moreover, the incidence of adverse events was almost identical to that in previous pivotal trials (1,2,4) and no treatment-related deaths or severe complications with the reconstruction flap were seen. Considering that most patients (72%) were ECOG-PS 0 and the small sample size, these results indicted the tolerability and feasibility of adjuvant 3W-CDDP/RT for Japanese patients with post-operative high-risk SCCHN.…”
Section: Discussionsupporting
confidence: 77%
“…These significant benefits of post-operative 3W-CDDP/RT were further supported by a combined analysis of RTOG 9501 and EORTC 22931 (3). However, post-operative 3W-CDDP/RT is associated with greater toxicity than post-operative radiation therapy alone and the complete delivery rate of three cycles of cisplatin and RT in prior pivotal trials was only 60% (1,2,4).…”
Section: Introductionmentioning
confidence: 93%
“…16,17 However, a comparison of data that were obtained in a nonrandomized study with OSCC patients treated with surgery alone or adjuvant chemotherapy revealed no evidence for improved cancer control or disease-specific survival in patients who received adjuvant therapy. 11,18 Similarly, a meta-analysis of adjuvant, neoadjuvant, and concomitant chemotherapy for OSCC and other forms of head and neck cancer revealed only a small survival benefit in favor of chemotherapy.…”
mentioning
confidence: 99%
“…Additionally, cisplatin has been studied in the metastatic setting in gastric cancer, and response rates have generally been higher with cisplatin-containing regimens 5,6,24 . Cisplatin has also been used as a radiosensitizer in other malignancies, and compared with radiation alone, it was shown to be associated with improved survival outcomes 8,25,26 .…”
Section: Discussionmentioning
confidence: 99%